239 related articles for article (PubMed ID: 35570242)
1. Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan
Leonardi C; Zhu B; Malatestinic WN; Eastman WJ; Guo J; Murage MJ; Choong CK; Burge R; Blauvelt A
Adv Ther; 2022 Jul; 39(7):3214-3224. PubMed ID: 35570242
[TBL] [Abstract][Full Text] [Related]
2. Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population.
Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
Dermatology; 2022; 238(3):438-447. PubMed ID: 34710876
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
Blauvelt A; Shi N; Zhu B; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Murage MJ
J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
[TBL] [Abstract][Full Text] [Related]
4. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population.
Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
J Dermatolog Treat; 2022 Jun; 33(4):2270-2277. PubMed ID: 34264149
[TBL] [Abstract][Full Text] [Related]
5. Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.
Blauvelt A; Shi N; Murage MJ; Kern SA; Somani N; Burge R; Ridenour TL; Lew CR; Zimmerman NM; Zhu B
J Med Econ; 2022; 25(1):741-749. PubMed ID: 35615978
[TBL] [Abstract][Full Text] [Related]
6. Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
Armstrong A; González-Cantero A; Khattri S; Muzy G; Malatestinic WN; Lampropoulou A; Feely M; See SK; Mert C; Blauvelt A
Dermatol Ther (Heidelb); 2024 Apr; 14(4):933-952. PubMed ID: 38521874
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study.
Blauvelt A; Shi N; Murage M; Ridenour T; Lew C; Somani N; Zhu B; Zimmerman N; Kern S; Burge R
J Drugs Dermatol; 2022 Apr; 21(4):399-407. PubMed ID: 35389589
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.
Blauvelt A; Shi N; Somani N; Burge R; Zhu B; Ridenour T; Kern S; Lew C; Zimmerman N; Murage M
Clin Drug Investig; 2023 Mar; 43(3):185-196. PubMed ID: 36840815
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months.
Blauvelt A; Shi N; Burge R; Somani N; Ridenour TL; Zhu B; Atiya B; Lew CR; Zimmerman NM; Murage MJ
Dermatol Ther (Heidelb); 2021 Dec; 11(6):2133-2145. PubMed ID: 34652590
[TBL] [Abstract][Full Text] [Related]
10. Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.
Blauvelt A; Lomaga M; Burge R; Zhu B; Shen W; Shrom D; Dossenbach M; Pinter A
J Dermatolog Treat; 2020 Mar; 31(2):141-146. PubMed ID: 30799638
[No Abstract] [Full Text] [Related]
11. Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study.
Zhang M; Goren A; Lee S; DiBonaventura MD; Olson WH
J Dermatolog Treat; 2016 Aug; 27(4):339-45. PubMed ID: 26558924
[TBL] [Abstract][Full Text] [Related]
12. Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis.
Wu JJ; Armstrong A; Singh R; Cloutier M; Gauthier-Loiselle M; Gagnon-Sanschagrin P; Arikan D; Fleischer A; Guérin A; Ganguli A
J Drugs Dermatol; 2018 Nov; 17(11):1211-1218. PubMed ID: 30500143
[TBL] [Abstract][Full Text] [Related]
13. Psoriasis treatment patterns and outcomes with ixekizumab in a real-world setting: results from a single US dermatology referral practice.
Leonardi C; Tao R; Setayeshgar S; Wang S; Burge R; Zhu B; Malatestinic WN
J Dermatolog Treat; 2022 Jun; 33(4):2278-2284. PubMed ID: 34236934
[TBL] [Abstract][Full Text] [Related]
14. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database.
Sruamsiri R; Iwasaki K; Tang W; Mahlich J
BMC Dermatol; 2018 Jul; 18(1):5. PubMed ID: 29996929
[TBL] [Abstract][Full Text] [Related]
15. Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months.
Blauvelt A; Shi N; Burge R; Atiya B; Zhu B; Somani N; Ridenour T; Lew CR; Zimmerman NM; Murage MJ
Pharmacoecon Open; 2022 Nov; 6(6):871-880. PubMed ID: 36155891
[TBL] [Abstract][Full Text] [Related]
16. Switching biologics in children with psoriasis: Results from the BiPe cohort.
Phan C; Beauchet A; Reguiai Z; Severino-Freire M; Mazereeuw-Hautier J; Bursztejn AC; Barbarot S; Hadj-Rabia S; Girard C; Phan A; Lacour JP; Lasek A; Abasq C; Brenaut E; Perrussel M; Droitcourt C; Mallet S; Piram M; Fougerousse AC; Barthélémy H; Balguérie X; Mahé E;
Pediatr Dermatol; 2022 Jan; 39(1):35-41. PubMed ID: 34888920
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials.
Malatestinic W; Nordstrom B; Wu JJ; Goldblum O; Solotkin K; Lin CY; Kistler K; Fraeman K; Johnston J; Hawley LL; Sicignano N; Araujo A
J Manag Care Spec Pharm; 2017 Mar; 23(3):370-381. PubMed ID: 28230450
[TBL] [Abstract][Full Text] [Related]
18. A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab.
Blauvelt A; Burge R; Gallo G; Charbonneau B; Malatestinic W; Zhu B; Wan F; Lockshin B
Dermatol Ther (Heidelb); 2022 Mar; 12(3):701-714. PubMed ID: 35220545
[TBL] [Abstract][Full Text] [Related]
19. Patient reported health outcomes and non-adherence in psoriasis patients receiving adalimumab or ustekinumab for moderate to severe plaque psoriasis.
Goren A; Carter C; Lee S
J Dermatolog Treat; 2016; 27(1):43-50. PubMed ID: 26088404
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation of biologic treatment in patients with moderate-to-severe psoriasis in Japan.
Tada Y; Soliman AM; Ishii K; Sakuma R; Pinter A; Davis M; Nunag D; Buessing M; Puig L; Imafuku S
Exp Dermatol; 2024 May; 33(5):e15067. PubMed ID: 38757460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
